|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miyake M, Morizawa Y, Hori S, Tatsumi Y,
Onishi S, Owari T, Iida K, Onishi K, Gotoh D, Nakai Y, et al:
Diagnostic and prognostic role of urinary collagens in primary
human bladder cancer. Cancer Sci. 108:2221–2228. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang Y, Xu J and Zhang Q: Microplate
magnetic chemiluminescence immunoassay for detecting urinary
survivin in bladder cancer. Oncol Lett. 14:4043–4052. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li X, Wang Y, Xu J and Zhang Q: Sandwich
ELISA for detecting urinary Survivin in bladder cancer. Chin J
Cancer Res. 25:375–381. 2013.PubMed/NCBI
|
|
5
|
Ogihara K, Kikuchi E, Yuge K, Ito Y,
Tanaka N, Matsumoto K, Miyajima A, Asakura H and Oya M: Refraining
from smoking for 15 years or more reduced the risk of tumor
recurrence in non-muscle invasive bladder cancer patients. Ann Surg
Oncol. 23:1752–1759. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nam JK, Park SW, Lee SD and Chung MK:
Prognostic value of sex-hormone receptor expression in
non-muscle-invasive bladder cancer. Yonsei Med J. 55:1214–1221.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chou R, Selph SS, Buckley DI, Gustafson
KS, Griffin JC, Grusing SE and Gore JL: Treatment of
muscle-invasive bladder cancer: A systematic review. Cancer-Am
Cancer Soc. 122:842–851. 2016.
|
|
8
|
Soloway MS: ICUD-EAU International
consultation on bladder cancer 2012: Recommendations on bladder
cancer-progress in a cancer that lacks the limelight. Eur Urol.
63:1–3. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bloom HJ, Hendry WF, Wallace DM and Skeet
RG: Treatment of T3 bladder cancer: Controlled trial of
pre-operative radiotherapy and radical cystectomy versus radical
radiotherapy. Br J Urol. 54:136–151. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang R, He H, Mao G and Kong Z:
Upregulating DAB2IP expression via EGR-1 inhibition, a new approach
for overcoming fractionated-irradiation-induced cross-tolerance to
ionizing radiation and mitomycin C in tumor cells. Int J Radiat
Biol. 93:386–393. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kong Z, Xie D, Boike T, Raghavan P, Burma
S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT and Saha D:
Downregulation of human DAB2IP gene expression in prostate cancer
cells results in resistance to ionizing radiation. Cancer Res.
70:2829–2839. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He H, Chang R, Zhang T, Yang C and Kong Z:
ATM mediates DAB2IP-deficient bladder cancer cell resistance to
ionizing radiation through the p38MAPK and NF-κB signaling pathway.
Mol Med Rep. 16:1216–1222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhattacharya S, Ray RM and Johnson LR:
STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents
apoptosis in polyamine-depleted cells. Biochem J. 392:335–344.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shimura T: Acquired radioresistance of
cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat
Res. 52:539–544. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimura T: Targeting the AKT/cyclin D1
pathway to overcome intrinsic and acquired radioresistance of
tumors for effective radiotherapy. Int J Radiat Biol. 93:381–385.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen CL, Cen L, Kohout J, Hutzen B, Chan
C, Hsieh FC, Loy A, Huang V, Cheng G and Lin J: Signal transducer
and activator of transcription 3 activation is associated with
bladder cancer cell growth and survival. Mol Cancer. 7:782008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang C, Zhang W, Wang L, Kazobinka G, Han
X, Li B and Hou T: Musashi-2 promotes migration and invasion in
bladder cancer via activation of the JAK2/STAT3 pathway. Lab
Invest. 96:950–958. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sebolt-Leopold JS and Herrera R: Targeting
the mitogen-activated protein kinase cascade to treat cancer. Nat
Rev Cancer. 4:937–947. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen RJ, Ho YS, Guo HR and Wang YJ:
Long-term nicotine exposure-induced chemoresistance is mediated by
activation of Stat3 and downregulation of ERK1/2 via nAChR and
beta-adrenoceptors in human bladder cancer cells. Toxicol Sci.
115:118–130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Guo G, Song J, Cai Z, Yang J, Chen
Z, Wang Y, Huang Y and Gao Q: B7-H3 promotes the migration and
invasion of human bladder cancer cells via the PI3K/Akt/STAT3
signaling pathway. J Cancer. 8:816–824. 2017. View Article : Google Scholar : PubMed/NCBI
|
